 | • レポートコード：QYR2104Z6207 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療機器 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、心房細動（SPAF）治療における脳卒中予防のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経口用直接トロンビン阻害剤、経口用直接因子Xa阻害剤）、用途別市場規模（病院、診療所、外来手術センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・心房細動（SPAF）治療における脳卒中予防の市場動向 ・企業の競争状況、市場シェア ・心房細動（SPAF）治療における脳卒中予防の種類別市場規模（経口用直接トロンビン阻害剤、経口用直接因子Xa阻害剤） ・心房細動（SPAF）治療における脳卒中予防の用途別市場規模（病院、診療所、外来手術センター） ・心房細動（SPAF）治療における脳卒中予防の北米市場規模2016-2027（アメリカ、カナダ） ・心房細動（SPAF）治療における脳卒中予防のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・心房細動（SPAF）治療における脳卒中予防のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・心房細動（SPAF）治療における脳卒中予防の中南米市場規模2016-2027（メキシコ、ブラジル） ・心房細動（SPAF）治療における脳卒中予防の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Boehringer Ingelheim、Bayer、Johnson & Johnson、Bristol-Myers Squibb、Pfizer、Daiichi-Sankyo、Gilead） ・結論 |
Atrial fibrillation (AF) now a days has become a common and serious condition affecting almost 1-2% of the total population of age group 65 years and above.
Increase in the aging population leads to increase in the prevalence further leads to increase rick of premature death.
Market Analysis and Insights: Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market
The global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market.
Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Scope and Market Size
Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Oral Direct Thrombin Inhibitors
Oral Direct Factor Xa Inhibitors
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Boehringer Ingelheim
Bayer
Johnson & Johnson
Bristol-Myers Squibb
Pfizer
Daiichi-Sankyo
Gilead
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral Direct Thrombin Inhibitors
1.2.3 Oral Direct Factor Xa Inhibitors
1.3 Market by Application
1.3.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Perspective (2016-2027)
2.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Growth Trends by Regions
2.2.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Industry Dynamic
2.3.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Trends
2.3.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Drivers
2.3.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Challenges
2.3.4 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Revenue
3.1.1 Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Revenue (2016-2021)
3.1.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue
3.4 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Concentration Ratio
3.4.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue in 2020
3.5 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players Head office and Area Served
3.6 Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product Solution and Service
3.7 Date of Enter into Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Breakdown Data by Type
4.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Type (2022-2027)
5 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Breakdown Data by Application
5.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2016-2027)
6.2 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
6.2.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021)
6.2.2 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027)
6.2.3 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2027)
6.3 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
6.3.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021)
6.3.2 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027)
6.3.3 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2027)
6.4 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country
6.4.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2016-2021)
6.4.2 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2016-2027)
7.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
7.2.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2027)
7.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
7.3.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2027)
7.4 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country
7.4.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
8.2.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
8.3.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region
8.4.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2016-2027)
9.2 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
9.2.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2027)
9.3 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
9.3.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2027)
9.4 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country
9.4.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
10.2.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
10.3.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country
10.4.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Details
11.1.2 Boehringer Ingelheim Business Overview
11.1.3 Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.1.4 Boehringer Ingelheim Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
11.1.5 Boehringer Ingelheim Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.2.4 Bayer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
11.2.5 Bayer Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.3.4 Johnson & Johnson Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
11.3.5 Johnson & Johnson Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.4.4 Bristol-Myers Squibb Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.5.4 Pfizer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
11.5.5 Pfizer Recent Development
11.6 Daiichi-Sankyo
11.6.1 Daiichi-Sankyo Company Details
11.6.2 Daiichi-Sankyo Business Overview
11.6.3 Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.6.4 Daiichi-Sankyo Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
11.6.5 Daiichi-Sankyo Recent Development
11.7 Gilead
11.7.1 Gilead Company Details
11.7.2 Gilead Business Overview
11.7.3 Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.7.4 Gilead Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
11.7.5 Gilead Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral Direct Thrombin Inhibitors
Table 3. Key Players of Oral Direct Factor Xa Inhibitors
Table 4. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Regions (2016-2021)
Table 8. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Regions (2022-2027)
Table 10. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Trends
Table 11. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Drivers
Table 12. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Challenges
Table 13. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Restraints
Table 14. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Players (2016-2021)
Table 16. Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2020)
Table 17. Ranking of Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product Solution and Service
Table 21. Date of Enter into Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2016-2021)
Table 25. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2016-2021)
Table 29. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 61. Boehringer Ingelheim Company Details
Table 62. Boehringer Ingelheim Business Overview
Table 63. Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 64. Boehringer Ingelheim Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021) & (US$ Million)
Table 65. Boehringer Ingelheim Recent Development
Table 66. Bayer Company Details
Table 67. Bayer Business Overview
Table 68. Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 69. Bayer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021) & (US$ Million)
Table 70. Bayer Recent Development
Table 71. Johnson & Johnson Company Details
Table 72. Johnson & Johnson Business Overview
Table 73. Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 74. Johnson & Johnson Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021) & (US$ Million)
Table 75. Johnson & Johnson Recent Development
Table 76. Bristol-Myers Squibb Company Details
Table 77. Bristol-Myers Squibb Business Overview
Table 78. Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 79. Bristol-Myers Squibb Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021) & (US$ Million)
Table 80. Bristol-Myers Squibb Recent Development
Table 81. Pfizer Company Details
Table 82. Pfizer Business Overview
Table 83. Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 84. Pfizer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021) & (US$ Million)
Table 85. Pfizer Recent Development
Table 86. Daiichi-Sankyo Company Details
Table 87. Daiichi-Sankyo Business Overview
Table 88. Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 89. Daiichi-Sankyo Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021) & (US$ Million)
Table 90. Daiichi-Sankyo Recent Development
Table 91. Gilead Company Details
Table 92. Gilead Business Overview
Table 93. Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 94. Gilead Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021) & (US$ Million)
Table 95. Gilead Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Oral Direct Thrombin Inhibitors Features
Figure 3. Oral Direct Factor Xa Inhibitors Features
Figure 4. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Ambulatory Surgical Centers Case Studies
Figure 8. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Report Years Considered
Figure 9. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Regions: 2020 VS 2027
Figure 12. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Regions (2022-2027)
Figure 13. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Players in 2020
Figure 14. Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue in 2020
Figure 16. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2016-2021)
Figure 17. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2022-2027)
Figure 18. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2016-2027)
Figure 20. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2016-2027)
Figure 21. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2016-2027)
Figure 22. United States Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2016-2027)
Figure 26. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2016-2027)
Figure 27. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2016-2027)
Figure 28. Germany Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region (2016-2027)
Figure 38. China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2016-2027)
Figure 46. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2016-2027)
Figure 47. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2016-2027)
Figure 48. Mexico Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2016-2027)
Figure 54. Turkey Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Boehringer Ingelheim Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
Figure 58. Bayer Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
Figure 59. Johnson & Johnson Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
Figure 62. Daiichi-Sankyo Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
Figure 63. Gilead Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2016-2021)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
世界の心房細動（AF）治療市場規模・現状・予測（2021年-2027年） Atrial fibrillation is an abnormal heart rhythm characterized by rapid and irregular beating of the atria. Often it starts as brief periods of abnormal beating which become longer and possibly constant over time. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting…- 世界の心房細動（AF）診断市場規模・現状・予測（2021年-2027年） Atrial fibrillation (AF) is a type of cardiac arrhythmia which is caused by irregular electrical activities in the atria. It may occur with no symptoms but most common ones associated with it are fainting, palpitations, congestive failure of the heart or chest pain. Factors such as aging of populati…
- 世界の急性虚血性脳卒中診断・治療市場規模・現状・予測（2021年-2027年） According to a World Health Organization (WHO) estimate, around 17 million people die every year due to cardiovascular diseases. Market Analysis and Insights: Global Acute Ischemic Stroke Diagnosis and Treatment Market The global Acute Ischemic Stroke Diagnosis and Treatment market size is projected…
- 世界の脳卒中市場規模・現状・予測（2021年-2027年） Brain Stroke is one of the most common types of neurovascular disease in which either a clot blocks restricts supply of blood to the brain (ischemic) or blood vessels in the brain rupture (hemorrhagic). The vascular diseases affect normal functioning of the veins and arteries that constitute circula…
- 世界の経口血糖降下薬（OAD）治療市場規模・現状・予測（2021年-2027年） Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabet…